Mebendazole - BullFrog AI
Alternative Names: BF-222Latest Information Update: 03 Apr 2024
At a glance
- Originator Johns Hopkins University
- Developer BullFrog AI; Johns Hopkins University
- Class Anthelmintics; Antineoplastics; Benzimidazoles; Carbamates; Small molecules
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Glioblastoma
Most Recent Events
- 29 Mar 2024 BullFrog AI has patent protection for mebendazole in Europe, France, Japan, India, China, Israel, Switzerland, Italy, Ireland, Germany, Czech Republic, United Kingdom Spain and the USA
- 29 Mar 2024 Interim adverse events data from a phase I trial in Glioblastoma released byBullFrog AI
- 14 Dec 2023 BullFrog AI plans a phase II trial in Glioblastoma